Morgan Stanley Lowers Globus Medical's Price Target to $68.00, Maintains "Overweight" Rating.

Morgan Stanley analyst Drew Ranieri has lowered Globus Medical's (GMED) price target to $68.00 from $75.00, a 9.33% decrease. Despite this, the "Overweight" rating remains unchanged. The average 1-year target price for GMED is $85.91, with a 49.75% upside from the current price. The average brokerage recommendation is 2.3, indicating "Outperform" status.

Title: Morgan Stanley Lowers Price Target for Globus Medical, Maintains "Overweight" Rating

Morgan Stanley analyst Drew Ranieri has revised the price target for Globus Medical (GMED) from $75.00 to $68.00, a 9.33% decrease. Despite this adjustment, the firm has retained its "Overweight" rating on the stock [1]. The decision reflects the analyst's confidence in the MedTech sector's stability, particularly regarding procedural volumes and hospital capital expenditures as the second quarter progresses.

The average one-year price target for GMED is $85.91, implying a potential upside of 49.75% from the current price of $57.37 [1]. The consensus recommendation from 15 brokerage firms is currently 2.3, indicating an "Outperform" status [1].

Globus Medical reported Q1 2025 financial results, with worldwide net sales of $598.1 million, a 1.4% decrease year-over-year. GAAP net income reached $75.5 million, with GAAP EPS of $0.54 and non-GAAP EPS of $0.68 [2]. The company successfully returned to a debt-free status by paying off nearly $900 million of debt inherited from the NuVasive merger [2].

Key developments include a 2% growth in the US spine business, driven by high retention rates and strong product offerings. The company also launched two new products in Q1, which are expected to drive market penetration and enhance their product portfolio [2]. Additionally, the acquisition of Nevro Corporation is seen as a strategic move to expand into a $3 billion market space, enhancing Globus Medical's reach in the musculoskeletal market [2].

However, the company faced challenges such as a slight decline in Q1 revenue, down 0.8% on a constant currency basis, due to softer enabling technology sales and supply chain disruptions [2]. Enabling technology sales decreased by 31% compared to the previous year, attributed to an elongated selling cycle and market uncertainty [2].

Globus Medical has also announced a significant $500 million share repurchase program of its outstanding common stock, aiming to address a disconnect between its intrinsic value and current market valuation [2]. The program will be funded through cash reserves and has no time limit.

References:
[1] https://www.gurufocus.com/news/2976908/globus-medical-gmed-price-target-lowered-by-morgan-stanley-gmed-stock-news
[2] https://www.stocktitan.net/news/GMED/